Результаты поиска

Comprehensive analysis of pan-cancer reveals potential of ASF1B as a prognostic and immunological biomarker.

BackgroundAnti-silencing function 1 (ASF1) is a conserved histone H3-H4 chaperone protein. ASF1B, a paralog of ASF1, acts by promoting cell proliferation and influencing cell cycle progression. Although there is some evidence demonstrating that ASF1B plays a key role in the development, progression, and prognosis of certain cancers, there are no pan-cancer analyses of ASF1B.MethodsWe used a range of bioinformatics approaches to investigate the predictive role of ASF1B, including its correlation with prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), tumor microenvironm

Совпадение в полном тексте источника
… Interestingly, patients with LIHC (Figure 5G , p = 0.003) showed decreased PFI in early disease stages but increased PFI in late disease stages, while the opposite trend was observed in individuals with uterine carcinosarcoma UCS (Figure 5O , p = 0.006). … cell carcinoma (KIRP), (F) lower grade glioma (LGG), (G) liver cancer (LIHC), (H) lung adenocarcinoma (LUAD), (I) lung squamous cell carcinoma (LUSC), (J) mesothelioma (MESO), (K) pancreatic cancer (PAAD), (L) prostate cancer (PRAD), (M) stomach cancer (STAD), (N) thyroid cancer (THCA), (O) uterine carcinosarcoma …

Upregulation of TTK expression is associated with poor prognosis and immune infiltration in endometrial cancer patients.

BackgroundThreonine and tyrosine kinase (TTK) is associated with invasion and metastasis in various tumors. However, the prognostic importance of TTK and its correlation with immune infiltration in endometrial cancer (EC) remain unclear.MethodsThe expression profile of TTK was analyzed using data from The Cancer Genome Atlas (TCGA) and the Clinical Proteome Cancer Analysis Consortium (CPTAC). TTK protein and mRNA levels were verified in EC cell lines. Receiver operating characteristic (ROC) curve analysis was used to evaluate the ability of TTK to distinguish between normal and EC tissues. K-M

Совпадение в полном тексте источника
… renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate cancer; READ, rectum cancer; STAD, stomach cancer; THCA, thyroid cancer; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma … renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver cancer; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate cancer; READ, rectum cancer; STAD, stomach cancer; THCA, thyroid cancer; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma …

Реальные результаты лечения от рака яичников в мире после " Мирветуксимаб соравтансин " : результаты работы в университете.

Foreign Mirvetuximab Soravtansine (MIRV) — антитело-наркомания, ориентированная на фолатовый рецептор альфа (FRα), выраженная в большинстве раковых заболеваний яичников. В ходе испытаний были получены положительные результаты, однако были использованы жесткие критерии отбора, а эффективность и токсичность в реальном мире по-прежнему являются неполными. Мы провели оценку общего выживаемости (ОС), без прогрессии выживаемости (ПФС) и токсичности среди общего гинекологического онкологического населения, лечившегося с помощью MIRV, в отношении повторяющегося рака яичников. 2022 и апрель 2025. Демог

Совпадение в полном тексте источника
… There were two patients with low-grade serous carcinoma (3.0%), one with clear cell carcinoma (1.5%), and one with carcinosarcoma (1.5%). Stage IIIC was the most common stage at initial diagnosis (59.1%, 39/66). Most patients had more than five prior treatment regimens (37.9%, 25/66). … 35 to 39.9 | 3(4.5) Class 3: = 40 | 5(7.6) ECOG PS at first MIRV dose | 0 | 25(37.9) 1 | 32(48.5) 2 | 7(10.6) 3 | 2(3.0) Charlson comorbidity index | 1 to < 10 | 55(83.3) ≥ 10 | 11(16.7) Disease Characteristics Histology | High grade serous | 62(93.9) Low grade serous | 2(3.0) Clear cell | 1(1.5) Carcinosarcoma …

Keyword Index for Volume 93

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… psychological well being 1092 PTEN 124 public health 862 quality of life 200, 1202, 1236 quantitative RT–PCR 144, 799 quiescent 302 Rad51 137 radiation 590, 699 radiotherapy 849, 977 raltitrexed 1230 randomised 279, 757, 862 randomised controlled trial 41 ras effectors 319 RASSF2 1395 rat carcinosarcoma …

Nanomedicine for cancer patient-centered care.

Cancer is a leading cause of morbidity and mortality worldwide, and an increase in incidence is estimated in the next future, due to population aging, which requires the development of highly tolerable and low-toxicity cancer treatment strategies. The use of nanotechnology to tailor treatments according to the genetic and immunophenotypic characteristics of a patient's tumor, and to allow its targeted release, can meet this need, improving the efficacy of treatment and minimizing side effects. Nanomedicine-based approach for the diagnosis and treatment of cancer is a rapidly evolving field. Se

Совпадение в полном тексте источника
… , ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian high grade serous adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, ovarian undifferentiated carcinoma, primary peritoneal Carcinosarcoma, Primary Peritoneal … Clear Cell Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Unresectable Melanoma, Uterine Corpus Carcinosarcoma | Mayo Clinic | Phase 1 NCT02106598 | Targeted silica nanoparticles for real‐time image‐guided …

A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.

BUB1B, a member of the spindle assembly checkpoint family known as BUB1 mitotic checkpoint serine/threonine kinase B, has been associated with the promotion of tumor progression. Nevertheless, its specific contributions to tumorigenesis remain largely unexplored. This study seeks to offer a systematic and comprehensive analysis of the role of BUB1B in the progression of various cancers, with a particular focus on lung adenocarcinoma, utilizing a range of databases. We investigated BUB1B's role in pan-cancer using TCGA data, analyzing it with platforms like HPA, TIMER, TISIDB, GEPIA, cBioPortal

Совпадение в полном тексте источника
… As illustrated in Figure 3 A, BUB1B alterations were identified in 32 cancer types, with uterine carcinosarcoma exhibiting the highest frequency at 7.02%. … Uterine carcinosarcoma had the highest mutation rate, at 7.02%, followed by uterine corpus endometrial carcinoma (6.24%) and others. TMB has been identified as a potential biomarker for various cancers, as assessed by the total number of somatically encoded mutations [ 27 , 28 ]. …

A ceRNA regulatory network in systemic lupus erythematosus and its molecular interplay with cancer.

BackgroundSystemic lupus erythematosus (SLE) is an autoimmune disease defined by the production of autoantibodies and involves multiple organs and systems. Although there are reports on SLE, data on its pathogenesis is limited.MethodsUsing R language software, we constructed a competing endogenous RNA (ceRNA) network. We then utilized the Search Tool for Recurring Instances of Neighbouring Genes (STRING) and cytoHubba databases to generate a protein-protein interaction (PPI) network, which led to the identification of hub genes. The top two hub genes with the highest Maximal Clique Centrality

Совпадение в полном тексте источника
… carcinoma; LIHC, liver hepatocellular carcinoma; WT, Wilms tumor; SKCM, skin cutaneous melanoma; BLCA, bladder urothelial carcinoma; THCA, thyroid carcinoma; READ, rectum adenocarcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; TGCT, testicular germ cell tumors; UCS, uterine carcinosarcoma … leukemia-recurrence; CHOL, cholangiocarcinoma; SARC, sarcoma; KICH, kidney chromophobe; BRCA, breast invasive carcinoma, NB, neuro blastoma, ESCA, esophageal carcinoma; STES, stomach and esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; PCPG, pheochromocytoma and paraganglioma; UCS, uterine carcinosarcoma …

mRNA вакцины для профилактики и лечения заболеваний.

mRNA вакцины стали высокоэффективными стратегиями в области профилактики и лечения болезней, в значительной степени, хотя и не полностью благодаря их выдающимся показателям в последние годы в борьбе с глобальной чумой. COVID-19. Огромное превосходство вакцин MRNA в том, что касается их эффективности, безопасности и крупномасштабного производства, побуждает фармацевтическую промышленность и биотехнологические компании распространять их применение на различные заболевания, несмотря на несомненные проблемы в проектировании, изготовлении и способе управления. В настоящем обзоре рассматриваются тех

Резюме ЭСП 2013.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting.

Doxorubicin (DOX), a widely used drug in cancer chemotherapy, induces cell death via multiple intracellular interactions, generating reactive oxygen species and DNA-adducted configurations that induce apoptosis, topoisomerase II inhibition, and histone eviction. Despite its wide therapeutic efficacy in solid tumors, DOX often induces drug resistance and cardiotoxicity. It shows limited intestinal absorption because of low paracellular permeability and P-glycoprotein (P-gp)-mediated efflux. We reviewed various parenteral DOX formulations, such as liposomes, polymeric micelles, polymeric nanopar

Совпадение в полном тексте источника
… 6.5) and intratumor cellular (pH 5.5) environments than at pH 7.4 | [ 65 ] pH-sensitive PMs | DOX-loaded micelle (DSPE-PEG2000/OA = 10:6), IV | 4T1 tumor-bearing mouse | pH-sensitive DOX release, 7-fold tumor shrinkage | [ 66 ] ROS-sensitive liposomes | DOPE/Egg PC/DDA = 37.5/60/2.5%, IV | Walker 256 carcinosarcoma-bearing … PAA-PF127-PAA-PM showed >80% viability at concentrations of <300 μg/mL; moreover, it showed a 3-fold higher apoptosis rate than free DOX in a Walker 256 carcinosarcoma-bearing rat [ 104 ]. Pluronic F127 micelles also exhibited a P-gp inhibitory effect [ 45 ]. …

NTP Toxicology and Carcinogenesis Studies of Benzene (CAS No. 71-43-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).

Benzene ranks 16th in production volume for chemicals produced in the United States, with approximately 9.9 billion pounds being produced in … ary gland carcinomas were found in mid dose and high dose female mice (0/49; 2/45; 5/50; 10/49) and carcinosarcomas in high dose female mice (0/49; 0/45; 1/50; 4/49). Increased incidences of various uncommon neoplastic and nonneoplastic lesions of the ovary (papillary cystadenoma, luteoma, granulosa cell tumor, tubular adenoma, benign mixed tumor, epithelial hyp …

Keyword Index for Volume 88

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… 1157 c- myc 1143 C4.4a 579 CA-19-9 1248 calcitonin 1537 cancer 163, 223, 270, 684 cancer immunotherapy 1292 cancer registries 1693 cancer susceptibility 487 cancer therapy 613 capecitabine 782 CAR 1411 carbonic anhydrase 1065 carcinogenesis 733, 740, 1217, 1501, 1735 carcinoma 702, 1543 carcinosarcoma …

Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies.

Despite the success of targeted therapies in cancer treatment, therapy-induced resistance remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via phenotypic switching driven by intrinsic or induced cell plasticity. Several reversible mechanisms have been proposed to circumvent tumor cell plasticity, including epigenetic modifications, regulation of transcription factors, activation or suppression of key signaling pathways, as well as modification of the tumor environment. Epithelial-to-mesenchymal transition, tumor cell and cancer stem cell formation also serv

Совпадение в полном тексте источника
… Galunisertib + Paclitaxel/Carboplatin Patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary 26 I Active, not recruiting NCT02688712 Rectal adenocarcinoma Galunisertib + Capecitabine + Fluorouracil + Surgery + Radiation Patients with locally advanced rectal adenocarcinoma … | Galunisertib + Paclitaxel/Carboplatin | Patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary | 26 | I | Active, not recruiting NCT02688712 | Rectal adenocarcinoma | Galunisertib + Capecitabine + Fluorouracil + Surgery + Radiation | Patients with locally advanced …

Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG).

Several animal models, as well as a number of cell culture experiments, indicate a prophylactic effect of bisphosphonates in respect of subsequent bone metastasis. Moreover, in preliminary clinical trials involving patients with advanced breast cancer and local or remote metastases, biophosphonates produced a reduction in new skeletal metastases. This overview summarizes and discusses the results of the latest investigations. It opens with a section on the pathophysiology of bone metastasis, which is followed by a report on animal models and first studies of bisphosphonate treatment as a new a

Совпадение в полном тексте источника
… Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1-bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256. Oncology. 1988;45(1):41–46. doi: 10.1159/000226528. Luckman S. …

TLN1: an oncogene associated with tumorigenesis and progression.

Talin-1 (TLN1), encoded by the TLN1 gene, is a focal adhesion-related protein capable of binding various proteins in the cytoskeleton. It is also expressed at high levels in many cancers wherein it influences cellular adhesion and the activation of integrins. TLN1 is also capable of promoting tumor cell invasivity, proliferation, and metastatic progression, in addition to being a relevant biomarker and therapeutic target in certain cancers. The present review offers a comprehensive overview of current knowledge regarding TLN1 with respect to its structural properties, functions, and role in tu

Совпадение в полном тексте источника
… Papillary Cell Carcinoma (KIRP), Brain Lower Grade Glioma (LGG), Lung Adenocarcinoma (LUAD), Ovarian Serous Cystadenocarcinoma (OV), Pheochromocytoma and Paraganglioma (PCPG), Rectum Adenocarcinoma (READ), Skin Cutaneous Melanoma (SKCM), Testicular Germ Cell Tumors (TGCT), Thymoma (THYM), and Uterine Carcinosarcoma … TLN1 gene expression is lower in UCS (uterine carcinosarcoma) tumor samples (n = 57) compared to paired normal tissues (n = 78), with P ≤ 0.05 L . …

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.

The HER2-targeted antibody-drug conjugate trastuzumab emtansine (T-DM1) is approved for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and taxane therapy, and has also demonstrated efficacy in the adjuvant setting in incomplete responders to neoadjuvant therapy. Despite its objective activity, intrinsic and acquired resistance to T-DM1 remains a major clinical challenge. T-DM1 mediates its activity in a number of ways, encompassing HER2 signalling blockade, Fc-mediated immune response and payload-mediated microtubule poisoning. Resistance mechanisms relating t

Совпадение в полном тексте источника
… been proposed to be a suitable treatment option for tumours with low HER2 expression that are less sensitive to T-DM1. 59 , 62 The agent is currently in Phase 2 and 3 trials for the treatment of HER2-positive metastatic breast cancer, gastric, colorectal, uterine and non-small cell lung cancers plus carcinosarcoma … Menderes G Bonazzoli E Bellone S Black J Predolini F Pettinella F SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/Neu expression Clin. …

Application Of Adoptive Immunotherapy In Ovarian Cancer.

Ovarian cancer (OC) has been the most fatal gynecological disease that threatens women's health. Surgery and platinum-based chemotherapy are the basic ovarian cancer treatments that can improve survival, but the five-year survival rate has not improved because of delayed diagnosis, drug resistance, and recurrence. Novel treatments are needed to improve the prognosis and survival rate of ovarian cancer patients. In recent years, adoptive cell therapy (ACT) has received increasing attention as an emerging therapeutic strategy in the treatment of solid tumors including OC. ACT has shown promising

Совпадение в полном тексте источника
… Quality of Life (QOL) / / / NCT03610490 Recruiting Ovarian Carcinosarcoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Ovarian Carcinoma, etc Autologous Tumor Infiltrating Lymphocytes MDA-TIL ORR 1. Complete response rate (CRR) 2. Disease control rate (DCR) 3. … Quality of Life (QOL) | / | / | / NCT03610490 | Recruiting | Ovarian Carcinosarcoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Ovarian Carcinoma, etc | Autologous Tumor Infiltrating Lymphocytes MDA-TIL | ORR | 1. Complete response rate (CRR) 2. Disease control rate (DCR) 3. …

Bispecific antibodies in the treatment of epithelial ovarian, endometrial, and cervical cancer: an overview of current applications, challenges, and emerging opportunities.

Gynecological cancer remains one of the leading causes of mortality worldwide. Recent advances in genomic and molecular sequencing have significantly enhanced our understanding of the biological pathways that drive tumor progression and resistance to therapy. Targeted therapies, including monoclonal antibodies (mAbs), have revolutionized cancer treatment by selectively interfering with oncogenic proteins expressed on cancer cells. However, the long-term clinical benefit is often limited due to the emergence of drug resistance, frequently mediated by compensatory signaling pathways or immune es

Совпадение в полном тексте источника
… Drug name | Targets | Setting | Phase | n | Results | TEAEs/TRAEs/irAEs G ≥ 3* (in at least 5% of pts) and any grade CRS/IRR/ICANS** (%) TAA mechanism Zanidatamab (ZW25) [ 54 ] | HER2 (ECD2) × HER2 (ECD4) | R/M EC/carcinosarcoma ≤ 2 lines | 2 | 16 | ORR: 6.2% mPFS: 1.7 mths (90% CI: 1.6–4.1 mths) OS: … In a phase II study enrolling 16 patients with HER2-overexpressing metastatic endometrial carcinoma or carcinosarcoma, the ORR was modest (6.2%), with only one PR reported. However, the clinical benefit rate at 24 weeks was 37.5%. …

Short- and Long-Term Prognosis in Hemodynamically Stable Pulmonary Embolism With Unresectable or Metastatic Malignancies: The Role of Performance Status.

BackgroundThe simplified Pulmonary Embolism Severity Index (sPESI) has limitations when evaluating acute pulmonary embolism (PE) in patients with concurrent malignancy. Despite its utility in predicting outcomes among cancer patients, the role of the Eastern Cooperative Oncology Group Performance Status (ECOG PS) in acute PE remains underexplored. This study aims to assess the prognostic significance of ECOG PS ≥ 3 on short- and long-term mortality in acute PE with malignancy, correlating it with the sPESI.Methods and resultsWe retrospectively analyzed 44 hemodynamically stable acute PE patien

Совпадение в полном тексте источника
… Carcinosarcoma: 1 case. Clear cell adenosquamous carcinoma: 1 case. De-differentiated liposarcoma: 1 case. DLBCL: 1 case. MM: 1 case. Invasive ductal carcinoma: 1 case. Metaplastic carcinoma: 1 case. Leiomyosarcoma: 1 case. Endometrioid carcinoma: 1 case. Epithelial carcinoma: 1 case. …

26S Proteasome Non-ATPase Regulatory Subunits 1 (PSMD1) and 3 (PSMD3) as Putative Targets for Cancer Prognosis and Therapy.

Ever since the ubiquitin proteasome system was characterized, efforts have been made to manipulate its function to abrogate the progression of cancer. As a result, the anti-cancer drugs bortezomib, carfilzomib, and ixazomib targeting the 26S proteasome were developed to treat multiple myeloma, mantle cell lymphoma, and diffuse large B-cell lymphoma, among others. Despite success, adverse side effects and drug resistance are prominent, raising the need for alternative therapeutic options. We recently demonstrated that knockdown of the 19S regulatory components, 26S proteasome non-ATPase subunit

Совпадение в полном тексте источника
… diseases analyzed in cBioportal were similar to those analyzed in UALCAN, with the addition of adrenocortical carcinoma (ACC), colon adenocarcinoma (COAD), diffuse large B-cell lymphoma (DLBCL), low grade glioma (LGG), mesothelioma (MESO), ovarian cancer (OV), tenosynovial giant cell tumor (TGCT), uterine carcinosarcoma …